Clinical evaluation of Dyslipidemia among type II diabetic patients at Public hospital Penang, Malaysia
Tóm tắt
Global views emphasize the need for early; effective intervention against the atherogenic dyslipidemia associated with type 2 diabetes and metabolic syndrome to reduce the risk of premature cardiovascular diseases. Our aim was to determine the clinical practices and compliance among dyslipidemia with type II diabetes and hypertension in multiracial society. Study was carried out in out-patient department of General hospital Penang over a period of ten months (Jan - Oct 2008). Study reflects the retrospective data collection covering a period of three years from Jan 2005 - Dec 2007. Universal sampling technique was used to select all the patients' undergone treatment for diabetes type II and dyslipidemia. All the concerned approvals were obtained from Clinical research Committee (CRC). Data was analyzed by using SPSS 15®. A total of 501 diabetes type 2 patients with dyslipidemia were identified in this study. The demographic data showed that 55.9% (n = 280) were female patients and 44.1% (n = 221) were males. Patients on combination therapy of metformin with other antidiabetic agent were 79%, while 21% were on monotherapy. Lovastatin was received as monotherapy in 83% of study population, while only 17% were on combination with gemfibrozil. Means of FPG and lipid profile were reduced from the initial (2005) to the latest level (2007) significantly (p < 0.001). Only 0.89% decrease in mean weight with S.D 13.1 as compared to initial S.D 12.8 after three years of Cohort. While in description 35.2% representatives gain weight with majority of males (71.5%), 52.3% with weight loss of 1-3 pounds majority (69.3%) with female respondents and rest 12.4% remains with same weight with mix gender distribution. Metformin and lovastatin use among patients of type 2 diabetes and dyslipidemia is significantly improved the clinical outcomes. No significant association of metformin or lovastatin is found against the hypertension. Metformin and calcium channel blocker combination therapy was found to be the best choice in the co-treatment of diabetes and hypertension.
Tài liệu tham khảo
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854–65. Erratum: p 1558
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al.: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963–72.
Selby JV, Ettinger B, Swain BE, Brown JB: First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 1999, 22:38–44.
Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV: Comparative outcomes study of metformin intervention versus conventional approach. The COSMIC Approach Study. Diabetes Care 2005, 28:539–43.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003, 163:2594–602.
Salpeter S, Greyber E, Pasternak G, Salpeter E: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006, (1):CD002967.
Holstein A, Stumvoll M: Contraindications can damage your health--is metformin a case in point? Diabetologia 2005, 48:2454–9.
Tahrani AA, Varughese GI, Scarpello JH, Hanna FWF: Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007, 335:508–12.
Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345–51.
Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583–90.
Lalau JD, Race JM: Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'. Diabetes Obes Metab 2001, 3:195–201.
Stades AME, Heikens JT, Erkelens DW, Holleman F, Hoekstra JBL: Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004, 255:179–87.
Ellis AK, Iliescu EA: Metformin-associated lactic acidosis in a low risk patient. Can J Clin Pharmacol 2001, 8:104–6.
Chu CK, Chang YT, Lee BJ, Hu SY, Hu WH, Yang DY: Metformin-associated lactic acidosis and acute renal failure in a type 2 diabetic patient. J Chin Med Assoc 2003, 66:505–8.
Brassøe R, Elkmann T, Hempel M, Gravholt CH: Fulminant lactic acidosis in two patients with type 2 diabetes treated with metformin. Diabet Med 2005, 22:1451–3.
DePalo VA, Mailer K, Yoburn D, Crausman RS: Lactic acidosis. Lactic acidosis associated with metformin use in treatment of type 2 diabetes mellitus. Geriatrics 2005, 60:36–41. 39
UK Prospective Diabetes Study 27: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997, 20:1683–1687.
Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM: Lowdensity lipoprotein size, pravastatin treatment, and coronary events. JAMA 2001, 286:1468–1474.
Sacks FM, Campos H: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003, 88:4525–4532.
Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G: Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol 2006, 97:943–946.
Kendall DM, Bergenstal RM: Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care 2001, 7:S327-S343.
Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB: Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM: a populationbased study. Diabetes Care 1993, 16:1022–1025.
Sulaiman Azhar S, Zaki Nada F, Gillani Wasif S: Comibined therapy in Dyslipidemia and Hyperglycemia of Diabetes Mellitus type II., Clinical Medicine Insight. Therapeutics 2010, 2:1–8.
Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR: Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective diabetes study (UKPDS 57). Diabetes Care 2002, 25:330–336.
Ward Dean: Biological Aging Measurement Clinical Applications. In The Center for Bio-Gerontology. Pensacola, Florida; 1988.
Ward Dean: Metformin: Life Extension Drug - Weight Loss Drug. International Anti-Aging System 2291:
Ward Dean: Metformin: The Most effective Life extension Drug. International Anti-Aging System 801:
Deutsch JC, Santhosh-Kumar CR, Kolhouse JF: Efficacy of Metformin in non-insulin-dependent diabetes mellitus. NEJM 1996,334(4):269. Dilman, Vladimir, and Dean, Ward
Vladimir Dilman, Ward Dean: The Neuroendocrine Theory of Aging, The Center for Bio-Gerontology. Pensacola, Florida; 1992.
The Diabetes Control and Complications Trial Research Group: The effect on intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977–986.
Charles MA, Eschwege E: Prevention of Type 2 Diabetes: Role of Metformin. Drugs 1999,58(Suppl 1):71–73.
Cusi K, DeFronzo RA: Metformin: a review of its Metabolic effects. Diabetes Reviews 1998,V6(N2):89–131.
Joshi SR: Metformin: Old wine in new bottle-evolving technology and therapy in diabetes. J Assoc Physicians India 2005, 53:963–72.
Petersen JS, Andersen D, Muntzel MS, Diemer NH, Holstein-Rathlou NH: Intracerebroventricular metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. Am J Hypertens 2001, 14:1116–22.
Fontbonne A, Charles MA, Juhan-Vague I, et al.: The effect of Metformin on the metabolic abnormalities associated with upper body fat distribution. Results of the BIGPRO 1 trial. Diabetes Care 1996, 19:920–6.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000,23(suppl 2):B21-B29.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998,352(9131):837–853.
Rae N, Secnik K, Dilla T, Lara N, Badı'a X: Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain. Patient Prefer Adherence 2008, 2:87–95.